Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12172501rdf:typepubmed:Citationlld:pubmed
pubmed-article:12172501lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:12172501lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:12172501lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:12172501lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:12172501lifeskim:mentionsumls-concept:C0045093lld:lifeskim
pubmed-article:12172501pubmed:issue6lld:pubmed
pubmed-article:12172501pubmed:dateCreated2002-8-12lld:pubmed
pubmed-article:12172501pubmed:abstractTextWe have examined the cytotoxic effect of gemcitabine in intravesical therapy using an in vitro co-cultured spheroid model composed of transitional cell carcinoma (TCC) and fibroblasts from both human and rat species. Immunohistochemistry analysis of the co-cultured spheroids, using cytokeratin-13 and vimentin antibodies against TCC and fibroblasts, respectively, showed the central location of fibroblasts within the spheroid, whereas TCC formed the peripheral layers. Spheroids composed of human TCC and fibroblasts (MGH-U3/CRL-1120 or RT-112/CRL-1120) as well as rat TCC and their corresponding fibroblasts (AY-27/RF-Ed1) displayed the same drug tolerance profile after an exposure of 0, 1, 3, 5, 7 and 14 days. As confirmed by time-lapse photography, MTT essay and vital dye staining, gemcitabine selectively killed the human and rat bladder cancer cell lines, but did not affect un-transformed human and rat fibroblast lines.lld:pubmed
pubmed-article:12172501pubmed:languageenglld:pubmed
pubmed-article:12172501pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:citationSubsetIMlld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12172501pubmed:statusMEDLINElld:pubmed
pubmed-article:12172501pubmed:monthJullld:pubmed
pubmed-article:12172501pubmed:issn0959-4973lld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:WongK KKKlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:MooreR BRBlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:MackeyJJlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:HaganJ AJAlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:KarmaliSSlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:KilaniR TRTlld:pubmed
pubmed-article:12172501pubmed:authorpubmed-author:TamimiYYlld:pubmed
pubmed-article:12172501pubmed:issnTypePrintlld:pubmed
pubmed-article:12172501pubmed:volume13lld:pubmed
pubmed-article:12172501pubmed:ownerNLMlld:pubmed
pubmed-article:12172501pubmed:authorsCompleteYlld:pubmed
pubmed-article:12172501pubmed:pagination557-66lld:pubmed
pubmed-article:12172501pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:meshHeadingpubmed-meshheading:12172501...lld:pubmed
pubmed-article:12172501pubmed:year2002lld:pubmed
pubmed-article:12172501pubmed:articleTitleSelective cytotoxicity of gemcitabine in bladder cancer cell lines.lld:pubmed
pubmed-article:12172501pubmed:affiliationDepartment of Experimental Surgery and Division of Urology, University of Alberta, Edmonton, Canada.lld:pubmed
pubmed-article:12172501pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12172501lld:pubmed